‫CGTN : بينغ ليوان تلقي كلمة عبر مؤتمر بالفيديو حول اليوم العالمي لمكافحة السل 2022

بكين، 25 مارس 2022 / PRNewswire / — حضرت بينغ ليوان، زوجة الرئيس الصيني شي جين بينغ وسفيرة النوايا الحسنة لمنظمة الصحة العالمية للسل وفيروس نقص المناعة البشرية/الإيدز، مؤتمرًا بالفيديو لليوم العالمي للسل 2022 يوم الخميس.

وقالت بينغ: “خلال السنوات الأخيرة، وبفضل العمل الشاق لمنظمة الصحة العالمية والجهود المشتركة للمجتمع الدولي، حقق العالم تقدما ملحوظا في مكافحة السل”.

“تأخذ الحكومة الصينية الوقاية من السل وعلاجه على محمل الجد وقد أدرجتهما ضمن استراتيجية الصين الصحية. وأنشئت صناديق خاصة، وتم توفير فحوص المتابعة المجانية والأدوية المضادة للسل للمرضى، ويجري بذل المزيد من الجهود للترويج للتقنيات التشخيصية والأدوية الجديدة. ونتيجة لذلك، تم الحفاظ على معدل الشفاء من السل فوق 90 في المائة”.

وأشارت بينغ إلى أن الحكومة الصينية وجميع قطاعات المجتمع تقدم الرعاية بنشاط لمرضى السل، مما يضمن عدم تأثر العلاج بالوباء.

كما شاركت تجربتها في المشاركة في الوقاية من السل ومكافحته في البلاد، حيث زارت العديد من المؤسسات الطبية والمدارس والمجتمعات المحلية في السنوات الماضية.

وأضافت: “في الصين، يعمل أكثر من مليون متطوع على زيادة الوعي العام بالوقاية من السل وعلاجه ومساعدة مرضى السل وتقديم الدعم لهم”.

يصادف 24 مارس اليوم العالمي السابع والعشرين للسل. وباعتبار السل أحد أقدم الأمراض المعدية، فقد ابتلي العالم به لقرون. ومع ذلك، وعلى الرغم من الوعي المتزايد والتصميم القوي على القضاء عليه، لا يزال المرض عنيدًا.

https://news.cgtn.com/news/2022-03-24/Peng-Liyuan-addresses-video-conference-on-World-TB-Day-2022-18EM3kcPNsc/index.html

الفيديو –  https://www.youtube.com/watch?v=TB1Uj74IDms  

Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine

  • U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current FDA approved or emergency use authorized-vaccines
  • NVX-CoV2373 will be evaluated in a head-to-head boosting trial in the United Arab Emirates to assess boosting options for a large number of the world’s population that have previously been vaccinated with inactivated COVID-19 vaccine

Novavax LogoGAITHERSBURG, Md., March 25, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine, is included in two trials now underway to evaluate its vaccine’s safety, immunogenicity, and reactogenicity as a booster amidst the ongoing COVID-19 pandemic. Both studies have initiated participant enrollment and will help to extend knowledge of how a range of vaccines, including Novavax’ COVID-19 vaccine, can be used as boosters following primary immunization.

“Additional COVID-19 booster studies are important to support vaccine choice for individuals, healthcare providers, and public health authorities,” said Filip Dubovsky, M.D., Chief Medical Officer, Novavax. “Our COVID-19 vaccine has already been recommended by multiple national policy bodies for both primary vaccination and booster settings in individuals 18 years of age and older. We look forward to adding to this body of evidence to support the expanded use of our protein-based vaccine.”

Novavax is participating in an ongoing Phase 1/2 trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) to assess homologous and heterologous boosting regimens in participants who received a primary series of a COVID-19 vaccine which has received full approval or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Participants will be given a third dose (> 12 weeks later) of either NVX-CoV2373 or one of the three COVID-19 vaccines that have already received EUA or full authorization from the FDA. The study is enrolling approximately 1,130 healthy individuals aged 18 years or older, about 180 of whom will receive NVX-CoV2373 as a heterologous booster. The trial is being conducted at approximately 10 clinical research sites and its primary objectives are to evaluate safety, reactogenicity, and immunogenicity of delayed heterologous or homologous vaccine doses after EUA dosed vaccines. Participants will be followed for 12 months, with topline results expected later this year and full results expected in 2023.

Novavax’ COVID-19 vaccine is also being evaluated in an observer-blinded Phase 3 study in the United Arab Emirates (UAE) to assess homologous versus heterologous boosting of participants who have already been immunized with Sinopharm’s COVID-19 vaccine. The safety and immunogenicity of a single booster dose of Novavax’ COVID-19 vaccine in adults previously vaccinated with Sinopharm’s COVID-19 vaccine will be evaluated. The study is enrolling approximately 1,000 participants aged 18 years or older at two centers in Abu Dhabi with the goal of providing data to support boosting with NVX-CoV2373 in the large number of individuals who have been vaccinated with inactivated vaccines globally. Participants will be followed for six months, with full results expected during the fourth quarter of 2022. The Ministry of Health and Prevention approved NVX-CoV2373 for emergency use in the UAE in December.

For more information about the NIAID-sponsored study, read here on clinicaltrials.gov. For more information about the study in the UAE, read here on clinicaltrials.gov. NVX-CoV2373 has not yet been authorized for use by the FDA, nor has it received heterologous or homologous booster approval in all the countries where it’s been authorized.

Important Safety Information
  • NVX-CoV2373 is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients.
  • Events of anaphylaxis have been reported with administration of COVID-19 vaccines. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. Close observation for at least 15 minutes is recommended and a second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of NVX-CoV2373.
  • Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.
  • Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
  • NVX-CoV2373 should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
  • The efficacy of NVX-CoV2373 may be lower in immunosuppressed individuals.
  • Administration of NVX-CoV2373 in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
  • The effects with NVX-CoV2373 may temporarily affect the ability to drive or use machines.
  • Individuals may not be fully protected until 7 days after their second dose. As with all vaccines, vaccination with NVX-CoV2373 may not protect all vaccine recipients.
  • The most common adverse reactions observed during clinical studies were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise.
About NVX-CoV2373

NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Novavax’ COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.

Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide. Existing authorizations leverage Novavax’ manufacturing partnership with Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax’ global supply chain.

About the NVX-CoV2373 Phase 3 trials

NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials.

PREVENT-19, a trial in the U.S. and Mexico that enrolled almost 30,000 participants aged 18 years and older, achieved 90.4% efficacy overall. It was designed as a 2:1 randomized, placebo-controlled, observer-blinded study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in the New England Journal of Medicine (NEJM).

A trial conducted in the U.K. with 14,039 participants aged 18 years and older was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in NEJM.

About Matrix-M™ Adjuvant

Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company’s COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu, its quadrivalent influenza investigational vaccine candidate. These vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on TwitterLinkedInInstagram and Facebook.

Forward-Looking Statements

Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373 and NanoFlu, its COVID-seasonal influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax’ plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax’ global supply chain, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, and the efficacy, safety and intended utilization of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Novavax’ Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com

Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
media@novavax.com

Logo – https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

 

‫ دار الأركان” تعلن عن عقد شراكة تطويرية مع “مجموعة عُمران” لتدشين مشروع “عايدة” المطل على بحر عُمان

 دبي، الإمارات العربية المتحدة ؛   25 مارس 2022 /PRNewswire/ —  وقعت “دار الأركان”، الشركة العقارية الرائدة في المملكة العربية السعودية ومنطقة دول مجلس التعاون الخليجي؛ اتفاقية مع الشركة العُمانية للتنمية السياحية (مجموعة عُمران)، الذراع التنفيذية للسلطنة لتنمية وتطوير القطاع السياحي؛ اتفاقية شراكة استراتيجية لتطوير مشروع “عايدة”، والذي سيكون أحد أكبر المشاريع العقارية متعددة الاستخدامات في منطقة يتي بالعاصمة العُمانية مسقط. وجاء توقيع الاتفاقية في إكسبو 2020 دبي.

Dar Al Arkan and OMRAN Group partner to develop AIDA overlooking the Sea of Oman

 ويعتبر هذا المشروع أول استثمار لشركة “دار الأركان” في سلطنة عُمان ، ويهدف إلى تحفيز ودعم نمو القطاع العقاري العُماني وفقاً لرؤية عُمان 2040. وتستثمر الشركتان في المشروع 6 مليارات ريال سعودي، على أن يتم تطويره على ثلاث مراحل و بمساحة إجمالية تناهز 3.5 مليون متر مربع.

وبموجب هذه الشراكة، ستطور “دار الأركان” هذا المشروع متعدد الاستخدامات في منطقتي يتي وينكت على بعد 20 دقيقة من وسط مدينة مسقط،  حيث يتألف المشروع الذي سيقام على ارتفاع 100 متر فوق شواطئ بحر عُمان من 3,500 وحدة سكنية. كما سيحوي المشروع على فندقين وساحة للمقاهي والمطاعم وممشى يضم متاجر فاخرة وغيرها من المرافق العامة.

وبهذه المناسبة، قال زياد الشعار، نائب رئيس مجلس الإدارة في شركة دار الأركان للتطوير العقاري : “نحن متحمسون جداً للمشاركة في تطوير هذا المشروع الفريد الذي يدعم مساعي عُمان في توفير تجربة استثنائية للمقيمين والسياح، إذ يساهم تطوير منطقتي يتي وينكت في تعزيز العروض السياحية لسلطنة عمان وترسيخ مكانتها كوجهة عالمية المستوى. ويرتكز مشروعنا هذا على تطلعاتنا الاستراتيجية في الارتقاء بمعايير وجودة قطاع العقارات في المنطقة، والأهم من ذلك أننا نتبع نهجاً مستداماً وصديقاً للبيئة في تطوير مشروع كبير متعدد الاستخدامات يتناسب مع خصائص المنطقة”.

من جانبه، قال هاشل بن عبيد المحروقي، الرئيس التنفيذي لمجموعة عُمران: “يسرنا التعاون مع ‘دار الأركان’ في هذا المشروع الرئيسي الذي يتم تطويره بخبرات عالمية المستوى؛ ويسرنا أكثر أننا نتشارك الرؤية نفسها فيما يخص ممارسات البناء المتوازنة والمستدامة، وهذا عامل حاسم بلا شك في نجاح المشروع. لقد تم تصميم مشروع يتي السياحي المتكامل بشكل استراتيجي ليكون امتداداً لمدينة مسقط بما يعكس تقدمها ورؤيتها الحضرية المستدامة. وسيصبح هذا المشروع محط أنظار الجميع بعروضه السكنية والترفيهية والثقافية والتجارية التي ستضع عُمان على خارطة السياحة الإقليمية والعالمية على حد سواء، عدا عن تشجيع الاستثمار الأجنبي وتحفيز القطاعات الاقتصادية الرئيسة التي تساعد في تحقيق رؤية السلطنة.”

 Photo – https://mma.prnewswire.com/media/1773930/Dar_Al_Arkan.jpg

Gate.io: Global Crypto Events Drive Industry Growth Through Increased Collaboration

Gate.io, one of the pioneering global cryptocurrency exchanges, shares how crypto events are essential for the continued development of the industry

MAJURO, Republic of the Marshall Islands, March 25, 2022 /PRNewswire/ — Over the past month, Gate.io, one of the world’s leading cryptocurrency exchanges, has joined, sponsored and spoken at several blockchain events hosted both online and at live venues across the globe.

Past events include MetaWeek, the World of Web3 Summit (WOW) and Crypto Expo 2022 in Dubai. Gate.io’s Chief Marketing Officer, Marie Tatibouet; NFT Magic Box Business Development Manager, Maria Rebello; and Business Development Manager, Renato Cheng, have represented the company at key events.

At the recently concluded MetaWeek, Gate.io joined ACTxDesign as official sponsors of the Art Node Vault, which was held live in Dubai and showcased through the Pax.World Metaverse The event held a Decentralized Art Show with high-profile female artists showcasing their talents, as well as two live painting sessions of NFT pieces, minted and auctioned on Gate.io’s NFT Magic Box platform. Art Node Vault also featured a panel discussion with leading women in the industry including Gate.io’s Chief Marketing Officer, Marie Tatibouet, highlighting the impact of female influence in the industry, in celebration of International Women’s Month.

“Events are key to the continuing growth and development of the crypto industry. Besides the value offered through networking, events allow thought leaders and experts in their respective fields to share valuable knowledge and insights, while upstarts gain the opportunity to show off their products and ideas. This is an exciting year in the industry as widespread adoption continues to grow and events start back up again,” said Marie Tatibouet, Chief Marketing Officer at Gate.io.

In the coming weeks and months, Gate.io will attend several other important events in the industry, including the MoneyLive Summit on March 28th and 29th, and the Crypto Compare Digital Asset Summit on March 30th, both of which are to be hosted in London. Gate.io will also have a notable presence at Paris Blockchain Week, one of the largest European events focused on the blockchain industry, which is set to be held on April 13th and 14th.

About Gate.io

Established in 2013, Gate.io is one of the pioneering cryptocurrency exchanges in the world and offers services related to the trading of multiple leading digital assets.

Beat Global Competitors, Hisense Received “Dubai Quality Global Award” Certified by Vice President of the UAE

QINGDAO, China, March 25, 2022 /PRNewswire/ — Hisense has been honored by the Department of Economy and Tourism (DET) in Dubai with the coveted Dubai Quality Global Awards 2022 on March 23rd. The announcement was made under the patronage of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice-President and Prime Minister of the UAE and Ruler of Dubai.

"Dubai Quality Global Award" by The Department of Economy and Tourism (DET)

Hisense, a brand with less than 10 years of operating history in the Middle East market, won the reward among many competitors, indicating that Hisense is recognized for its outstanding strengths. The candidates of the award are strictly selected for three to four months. The judges believe that under the impact of the pandemic, winning the “Dubai Quality Global Award” shows Hisense’s unremitting efforts to re-open to the world and its positive contributions to local economic recovery and development.

Since October 2021, Hisense has started the preparation and submission of the award. During the rigorous evaluation process, the DET in Dubai conducted a comprehensive evaluation of Hisense in different terms.

Hisense’s development strategy and events plan deeply impressed the judges, especially the local activities and services such as HiME App and Hisense Supporting Center. As a unique digital platform, HiME App can keep in touch with users in real-time and provide consumers with quick responses and services. Its 24/7 service model also makes Hisense more competitive in the local market. Hisense Support center is an exclusive platform for product experience and fast after-sales service. During the pandemic, Hisense launched free services and additional warranties, which made it easier and more convenient for local consumers to enjoy the company’s products and services.

“We are so proud of winning the award, and we appreciate the DET for seeing our efforts in the region, which encourages our company for a brighter future.” said Mr. Jason Ou, General Manager of Hisense Middle East and Africa Market, “Hisense has always adhered to high quality and advanced technology since developing the market in the Middle East and has entered a rapid development track locally.”

Hisense will always adhere to technology, integrity, and quality, and continue to create trustworthy products and services for global consumers, thereby continuously enhancing its brand awareness and competitiveness.

Photo – https://mma.prnewswire.com/media/1773898/1.jpg
Photo – https://mma.prnewswire.com/media/1773896/2.jpg
Photo – https://mma.prnewswire.com/media/1773895/3.jpg

Bybit Aims to be an Infrastructure Provider for Decentralization

 DUBAI, UNITED ARAB EMIRATES – Media OutReach – 25 March 2022 – Bybit, the world’s third most visited cryptocurrency exchange, said it is investing in technology that will drive revolutionary changes and prepare the world for decentralization.

At a fireside chat and at a panel discussion at the World Blockchain Summit Dubai 2022, Igneus Terrenus, Head of Communications at Bybit, said the centralized exchange was all about getting people behind a decentralized future.

“We run a very successful exchange business, and we are able to invest in projects that will prove to be fundamentally revolutionary. Bybit is the instigator and a major contributor of BitDAO — one of the world’s largest DAO in terms of treasury size. BitDAO has allocated hundreds of million dollars into blockchain gaming with Game7, Layer 2 scaling solutions with zkDAO and blockchain research with EduDAO and eight of the world’s most prestigious universities,” said Igneus Terrenus, Head of Communications at Bybit.

Web3 technologies need to mature before mass adoption could happen. But onboarding more people into the new space will contribute to a better technology stack and more opportunities. Bybit wants to be the provider of the infrastructure for the transition into a blockchain-powered decentralized future. “We see ourselves as a bridging agent to help people of all skill and knowledge levels to access web3 technologies and innovations they could use. We want to bring more people into the space because we truly see the value in that,” said Terrenus.

The World Blockchain Summit global series is organized by Trescon to connect global leaders, thinkers and investors in blockchain and crypto innovations. The 22nd global edition of the Summit was powered by Bybit and took place at Atlantis, The Palm in Dubai on March 23 and 24, 2022.

“Bybit’s core ethos is to support the next level of innovation, talent, and technology development. This is perfectly aligned with our vision to exist at the forefront of technological innovation,” Mithun Shetty, CEO of Trescon said. “We appreciate the support of Bybit, and all the great work we will be able to do because of this partnership,” he added.

About Bybit

Bybit is a cryptocurrency exchange established in March 2018 to offer a professional platform where crypto traders can find an ultra-fast matching engine, excellent customer service, and multilingual community support. The company provides innovative online spot and derivatives trading services, mining and staking products, as well as API support, to retail and institutional clients around the world, and strives to be the most reliable exchange for the emerging digital asset class. Bybit is the proud partner of Formula One racing team Oracle Red Bull Racing, esports teams like NAVI, Alliance, Astralis, and Virtus.pro; German soccer club Borussia Dortmund and Japanese soccer club Avispa Fukuoka.

For more information please visit: https://www.bybit.com/

For updates, please follow Bybit’s social media platforms on

https://discord.com/invite/bybit
https://www.facebook.com/Bybit
https://www.instagram.com/bybit_official/
https://www.linkedin.com/company/bybitexchange/
https://www.reddit.com/r/Bybit/
https://t.me/BybitEnglish
https://www.tiktok.com/@bybit_official
https://twitter.com/Bybit_Official
https://www.youtube.com/c/Bybit

For media inquiries, please contact: press@bybit.com